In Vivo Model Development for Polycythemia Vera

Protheragen offers comprehensive in vivo animal model development services for Polycythemia Vera (PV), leveraging advanced genetic and xenograft technologies to support drug discovery and mechanistic research. Our expertise in generating and characterizing robust murine models enables pharmaceutical and academic partners to accelerate the evaluation of novel therapeutics targeting PV.

Polycythemia Vera is a myeloproliferative neoplasm characterized by excessive erythrocyte production, most commonly driven by JAK2 mutations. Accurate animal models are essential for understanding disease mechanisms and testing new treatments. Protheragen utilizes Mus musculus (mouse) species, including well-characterized strains such as C57BL/6 and Ly5.1, to develop models that faithfully recapitulate the human disease. These models, featuring mutant JAK2 expression and bone marrow transplantation, enable the study of disease progression, therapeutic efficacy, and hematopoietic dynamics relevant to human PV.

Genetic Models (Transgenic and Conditional Transgenic)

Genetic models are established by introducing mutations such as JAK2 (V617F) into the mouse genome, either constitutively or conditionally, often under hematopoietic-specific promoters (e.g., Vav1). Techniques include the use of transgenic mice or hematopoietic stem cell transplantation from genetically modified donors. These models closely mimic the genetic etiology of human PV, providing high translational relevance. Advantages include stable, reproducible disease phenotypes and the ability to dissect molecular mechanisms. Primary applications are preclinical drug efficacy testing, mechanistic studies, and biomarker validation.

Xenograft Models

Xenograft models are generated by transplanting bone marrow cells, either from mice or humans harboring JAK2 (V617F) mutations, into immunocompromised or irradiated recipient mice. This approach enables the study of both murine and human disease cells within a living organism. Key advantages include flexibility in donor source, rapid disease induction, and the opportunity to evaluate human-specific therapies. These models are widely used for in vivo drug screening, evaluation of cell-based therapies, and investigation of disease microenvironment interactions.

Allograft Models

Allograft models involve the transplantation of bone marrow cells from genetically modified donor mice (e.g., JAK2-mutant) into syngeneic, typically irradiated, recipient mice. This method facilitates the study of disease progression in an immunocompetent setting, preserving host immune interactions. Advantages include reproducibility, controlled genetic background, and compatibility with immunological studies. Allograft models are particularly suited for evaluating immune responses, therapeutic efficacy, and disease pathophysiology in a setting that mirrors endogenous hematopoiesis.

Protheragen provides a turnkey solution for in vivo Polycythemia Vera model development, encompassing model design, generation, validation, and pharmacological evaluation. Our services include customized genetic engineering, bone marrow transplantation, and irradiation protocols tailored to your research objectives. Key efficacy endpoints and measurements include hematological profiling (RBC, WBC, platelet counts), spleen and liver pathology, bone marrow histology, JAK2 allele burden, and survival analysis. We offer advanced analytical capabilities such as flow cytometry, qPCR, next-generation sequencing, and cytokine profiling. Rigorous quality control is maintained through standardized procedures, validated assays, and comprehensive data reporting to ensure reproducibility and scientific integrity.

Partnering with Protheragen ensures access to scientifically validated, customizable in vivo Polycythemia Vera models and expert support throughout your research program. Our integrated approach accelerates the translation of experimental findings into clinical candidates, reducing development timelines and enhancing data reliability. Contact us today to discuss your project needs and leverage our expertise for your next breakthrough in Polycythemia Vera research.